Van beleggers
voor beleggers
desktop iconMarkt Monitor
  • Word abonnee
  • Inloggen

    Inloggen

    • Geen account? Registreren

    Wachtwoord vergeten?

Ontvang nu dagelijks onze kooptips!

word abonnee

Wat na ABLYNX welke aandeln kunnen veel groeien om welke redenen.

3 Posts
| Omlaag ↓
  1. [verwijderd] 1 februari 2018 11:34
    Merus, bispecifieke antibodies zijn de toekomst. bivoorbeeld: Basel, June 28, 2016 - Today Novartis announced that it has entered into a collaboration and licensing agreement with Xencor for the development of bispecific antibodies for treating cancer. The agreement is the latest in a series of acquisitions and strategic collaborations between Novartis and biotech companies that have helped bolster its deep and diverse immuno-oncology pipeline.

    Traditional monoclonal antibodies target and bind to a single antigen. Bispecific antibodies are engineered to recognize and target two different antigens, which makes them potentially more effective in targeting complex diseases. A T-cell engaging bispecific antibody is able to bind an antigen on a tumor cell with one arm and engage T-cells capable of their destruction with the other.
3 Posts
|Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Indices

AEX 923,71 +0,04%
EUR/USD 1,0802 -0,82%
FTSE 100 8.245,37 -0,48%
Germany40^ 18.547,30 -0,56%
Gold spot 2.290,71 -3,58%
NY-Nasdaq Composite 17.173,12 -0,09%

Stijgers

BESI
+2,85%
Nedap ...
+2,60%
Alfen ...
+2,55%
Sligro
+2,36%
HEIJMA...
+1,83%

Dalers

Arcadis
-5,00%
CTP
-2,50%
WDP
-2,48%
SIGNIF...
-2,07%
NX FIL...
-2,05%

Lees verder op het IEX netwerk Let op: Artikelen linken naar andere sites

Gesponsorde links